#BEGIN_DRUGCARD DB04005

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
63-39-8

# ChEBI_ID:
15713

# Chemical_Formula:
C9H15N2O15P3

# Chemical_IUPAC_Name:
({[({[(2S,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Uridine 5&#39;-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Uridine 5'-Triphosphate

# HET_ID:
UTP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H15N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18)/t4-,6-,7+,8+/m0/s1

# InChI_Key:
InChIKey=PGAVKCOVUIYSFO-ZAKLUEHWSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00075

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4005

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
484.1411

# Molecular_Weight_Mono:
483.968527356

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1UEI

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.07

# Predicted_LogS:
-1.8

# Predicted_Water_Solubility:
8.37e+00 g/l

# Primary_Accession_No:
DB04005

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5746425

# PubChem_Substance_ID:
46507277

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03210

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@@H]1[C@@H](O)[C@@H](O[C@H]1CO[P@](O)(=O)O[P@@](O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:51 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
UCK2

# Drug_Target_1_GenBank_ID_Gene:
D78335

# Drug_Target_1_GenBank_ID_Protein:
1655420

# Drug_Target_1_GeneCard_ID:
UCK2

# Drug_Target_1_Gene_Name:
UCK2

# Drug_Target_1_Gene_Sequence:
>786 bp
ATGGCCGGGGACAGCGAGCAGACCCTGCAGAACCACCAGCAGCCCAACGGCGGCGAGCCC
TTCCTTATAGGCGTCAGCGGGGGAACAGCTAGCGGCAAGTCTTCCGTGTGTGCTAAGATC
GTGCAGCTCCTGGGGCAGAATGAGGTGGACTATCGCCAGAAGCAGGTGGTCATCCTGAGC
CAGGATAGCTTCTACCGTGTCCTTACCTCGGAGCAGAAGGCCAAAGCCCTGAAGGGCCAG
TTCAACTTTGACCACCCGGATGCCTTTGACAATGAACTCATTCTCAAAACACTCAAAGAA
ATCACTGAAGGGAAAACAGTCCAGATCCCCGTGTATGACTTTGTCTCCCATTCCCGGAAG
GAGGAGACAGTTACTGTCTATCCCGCAGACGTGGTGCTCTTTGAAGGGATCCTGGCCTTC
TACTCCCAGGAGGTACGAGACCTGTTCCAGATGAAGCTTTTTGTGGATACAGATGCGGAC
ACCCGGCTCTCACGCAGAGTATTAAGGGACATCAGCGAGAGAGGCAGGGATCTTGAGCAG
ATTTTATCTCAGTACATTACGTTCGTCAAGCCTGCCTTTGAGGAATTCTGCTTGCCAACA
AAGAAGTATGCTGATGTGATCATCCCTAGAGGTGCAGATAATCTGGTGGCCATCAACCTC
ATCGTGCAGCACATCCAGGACATCCTGAATGGAGGGCCCTCCAAACGGCAGACCAATGGC
TGTCTCAACGGCTACACCCCTTCACGCAAGAGGCAGGCATCGGAGTCCAGCAGCAGGCCG
CATTGA

# Drug_Target_1_General_Function:
Nucleotide transport and metabolism

# Drug_Target_1_General_References:
11306702	Van Rompay AR, Norda A, Linden K, Johansson M, Karlsson A: Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
11494055	Koizumi K, Shimamoto Y, Azuma A, Wataya Y, Matsuda A, Sasaki T, Fukushima M: Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells. Int J Mol Med. 2001 Sep;8(3):273-8.
8812458	Ozaki K, Kuroki T, Hayashi S, Nakamura Y: Isolation of three testis-specific genes (TSA303, TSA806, TSA903) by a differential mRNA display method. Genomics. 1996 Sep 1;36(2):316-9.

# Drug_Target_1_HGNC_ID:
HGNC:12562

# Drug_Target_1_HPRD_ID:
01882

# Drug_Target_1_ID:
2697

# Drug_Target_1_Locus:
1q23

# Drug_Target_1_Molecular_Weight:
29299

# Drug_Target_1_Name:
Uridine-cytidine kinase 2

# Drug_Target_1_Number_of_Residues:
261

# Drug_Target_1_PDB_ID:
1XRJ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00485	PRK

# Drug_Target_1_Protein_Sequence:
>Uridine-cytidine kinase 2
MAGDSEQTLQNHQQPNGGEPFLIGVSGGTASGKSSVCAKIVQLLGQNEVDYRQKQVVILS
QDSFYRVLTSEQKAKALKGQFNFDHPDAFDNELILKTLKEITEGKTVQIPVYDFVSHSRK
EETVTVYPADVVLFEGILAFYSQEVRDLFQMKLFVDTDADTRLSRRVLRDISERGRDLEQ
ILSQYITFVKPAFEEFCLPTKKYADVIIPRGADNLVAINLIVQHIQDILNGGPSKRQTNG
CLNGYTPSRKRQASESSSRPH

# Drug_Target_1_Reaction:
ATP + uridine = ADP + UMP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Phosphorylates uridine and cytidine to uridine monophosphate and cytidine monophosphate. Does not phosphorylate deoxyribonucleosides or purine ribonucleosides. Can use ATP or GTP as a phosphate donor. Can also phosphorylate cytidine and uridine nucleoside analogs such as 6-azauridine, 5-fluorouridine, 4- thiouridine, 5-bromouridine, 4-N-acetylcytidine, 4-N- benzoylcytidine, 5-fluorocytidine, 2-thiocytidine, 5- methylcytidine, and 4-N-anisoylcytidine

# Drug_Target_1_SwissProt_ID:
Q9BZX2

# Drug_Target_1_SwissProt_Name:
UCK2_HUMAN

# Drug_Target_1_Synonyms:
Cytidine monophosphokinase 2
EC 2.7.1.48
UCK 2
Uridine monophosphokinase 2

# Drug_Target_1_Theoretical_pI:
6.68

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Core protein p21:Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
D90208

# Drug_Target_2_GenBank_ID_Protein:
221611

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
>9033 bp
ATGAGCACAAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCACAG
GACGTTAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGCGCAGG
GGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAACCTCGTGGA
AGGCGACAACCTATCCCCAAGGCTCGCCGGCCCGAGGGTAGGACCTGGGCTCAGCCCGGG
TACCCTTGGCCCCTCTATGGCAACGAGGGTATGGGGTGGGCAGGATGGCTCCTGTCACCC
CGTGGCTCTCGGCCTAGTTGGGGCCCCACAGACCCCCGGCGTAGGTCGCGTAATTTGGGT
AAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCATGGGGTACATTCCGCTTGTC
GGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCACATGGTGTCCGGGTTCTGGAGGAC
GGCGTGAACTATGCAACAGGGAATCTGCCCGGTTGCTCTTTCTCTATCTTCCTCTTAGCT
TTGCTGTCTTGTTTGACCATCCCAGCTTCCGCTTACGAGGTGCGCAACGTGTCCGGGATA
TACCATGTCACGAACGACTGCTCCAACTCAAGTATTGTGTATGAGGCAGCGGACATGATC
ATGCACACCCCCGGGTGCGTGCCCTGCGTCCGGGAGAGTAATTTCTCCCGTTGCTGGGTA
GCGCTCACTCCCACGCTCGCGGCCAGGAACAGCAGCATCCCCACCACGACAATACGACGC
CACGTCGATTTGCTCGTTGGGGCGGCTGCTCTCTGTTCCGCTATGTACGTTGGGGATCTC
TGCGGATCCGTTTTTCTCGTCTCCCAGCTGTTCACCTTCTCACCTCGCCGGTATGAGACG
GTACAAGATTGCAATTGCTCAATCTATCCCGGCCACGTATCAGGTCACCGCATGGCTTGG
GATATGATGATGAACTGGTCACCTACAACGGCCCTAGTGGTATCGCAGCTACTCCGGATC
CCACAAGCCGTCGTGGACATGGTGGCGGGGGCCCACTGGGGTGTCCTAGCGGGCCTTGCC
TACTATTCCATGGTGGGGAACTGGGCTAAGGTCTTGATTGTGATGCTACTCTTTGCTGGC
GTTGACGGGCACACCCACGTGACAGGGGGAAGGGTAGCCTCCAGCACCCAGAGCCTCGTG
TCCTGGCTCTCACAAGGCCCATCTCAGAAAATCCAACTCGTGAACACCAACGGCAGCTGG
CACATCAACAGGACCGCTCTGAATTGCAATGACTCCCTCCAAACTGGGTTCATTGCTGCG
CTGTTCTACGCACACAGGTTCAACGCGTCCGGGTGCCCAGAGCGCATGGCTAGCTGCCGC
CCCATCGATGAGTTCGCTCAGGGGTGGGGTCCCATCACTCATGATATGCCTGAGAGCTCG
GACCAGAGGCCATATTGCTGGCACTACGCGCCTCGACCGTGCGGGATCGTGCCTGCGTCG
CAGGTGTGTGGTCCAGTGTATTGCTTCACTCCGAGCCCTGTTGTAGTGGGGACGACCGAT
CGTTTCGGCGCTCCTACGTATAGCTGGGGGGAGAATGAGACAGACGTGCTGCTACTTAGC
AACACGCGGCCGCCTCAAGGCAACTGGTTTGGGTGCACGTGGATGAACAGCACTGGGTTC
ACCAAGACGTGCGGGGGCCCTCCGTGCAACATCGGGGGGGTCGGCAACAACACCTTGGTC
TGCCCCACGGATTGCTTCCGGAAGCACCCCGAGGCCACTTACACAAAGTGTGGCTCGGGG
CCCTGGTTGACACCCAGGTGCATGGTTGACTACCCATACAGGCTCTGGCACTACCCCTGC
ACTGTTAACTTTACCGTCTTTAAGGTCAGGATGTATGTGGGGGGCGTGGAGCACAGGCTC
AATGCTGCATGCAATTGGACTCGAGGAGAGCGCTGTGACTTGGAGGACAGGGATAGGTCA
GAACTCAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTCACC
ACCCTACCGGCCCTGTCCACTGGCTTGATCCATCTTCACCGGAACATCGTGGACGTGCAA
TACCTGTACGGTATAGGGTCGGCAGTTGTCTCCTTTGCAATCAAATGGGAGTATATCCTG
TTGCTTTTCCTTCTTCTGGCGGACGCGCGCGTCTGTGCCTGCTTGTGGATGATGCTGCTG
ATAGCCCAGGCTGAGGCCACCTTAGAGAACCTGGTGGTCCTCAATGCGGCGTCTGTGGCC
GGAGCGCATGGCCTTCTCTCCTTCCTCGTGTTCTTCTGCGCCGCCTGGTACATCAAAGGC
AGGCTGGTCCCTGGGGCGGCATATGCTCTCTATGGCGTATGGCCGTTGCTCCTGCTCTTG
CTGGCCTTACCACCACGAGCTTATGCCATGGACCGAGAGATGGCTGCATCGTGCGGAGGC
GCGGTTTTTGTAGGTCTGGTACTCTTGACCTTGTCACCATACTATAAGGTGTTCCTCGCT
AGGCTCATATGGTGGTTACAATATTTTATCACCAGAGCCGAGGCGCACTTGCAAGTGTGG
GTCCCCCCTCTCAATGTTCGGGGAGGCCGCGATGCCATCATCCTCCTTACATGCGCGGTC
CATCCAGAGCTAATCTTTGACATCACCAAACTCCTGCTCGCCATACTCGGTCCGCTCATG
GTGCTCCAGGCTGGCATAACTAGAGTGCCGTACTTTGTACGCGCTCAGGGGCTCATCCGT
GCATGCATGTTAGTGCGGAAGGTCGCTGGAGGCCACTATGTCCAAATGGCCTTCATGAAG
CTGGCCGCGCTGACAGGTACGTACGTATATGACCATCTTACTCCACTGCGGGATTGGGCC
CACGCGGGCCTACGAGACCTTGCGGTGGCAGTAGAGCCCGTCGTCTTCTCTGACATGGAG
ACTAAACTCATCACCTGGGGGGCAGACACCGCGGCGTGTGGGGACATCATCTCGGGTCTA
CCAGTCTCCGCCCGAAGGGGGAAGGAGATACTTCTAGGACCGGCCGATAGTTTTGGAGAG
CAGGGGTGGCGGCTCCTTGCGCCTATCACGGCCTATTCCCAACAAACGCGGGGCCTGCTT
GGCTGTATCATCACTAGCCTCACAGGTCGGGACAAGAACCAGGTCGATGGGGAGGTTCAG
GTGCTCTCCACCGCAACGCAATCTTTCCTGGCGACCTGCGTCAATGGCGTGTGTTGGACC
GTCTACCATGGTGCCGGCTCGAAGACCCTGGCCGGCCCGAAGGGTCCAATCACCCAAATG
TACACCAATGTAGACCAGGACCTCGTCGGCTGGCCGGCGCCCCCCGGGGCGCGCTCCATG
ACACCGTGCACCTGCGGCAGCTCGGACCTTTACTTGGTCACGAGGCATGCTGATGTCGTT
CCGGTGCGCCGGCGGGGCGACAGCAGGGGGAGCCTGCTTTCCCCCAGGCCCATCTCCTAC
CTGAAGGGCTCCTCGGGTGGACCACTGCTTTGCCCTTCGGGGCACGTTGTAGGCATCTTC
CGGGCTGCTGTGTGCACCCGGGGGGTTGCGAAGGCGGTGGACTTCATACCCGTTGAGTCT
ATGGAAACTACCATGCGGTCTCCGGTCTTCACAGACAACTCATCCCCTCCGGCCGTACCG
CAAACATTCCAAGTGGCACATTTACACGCTCCCACTGGCAGCGGCAAGAGCACCAAAGTG
CCGGCTGCATATGCAGCCCAAGGGTACAAGGTGCTCGTCCTAAACCCGTCCGTTGCCGCC
ACATTGGGCTTTGGAGCGTATATGTCCAAGGCACATGGCATCGAGCCTAACATCAGAACT
GGGGTAAGGACCATCACCACGGGCGGCCCCATCACGTACTCCACCTATTGCAAGTTCCTT
GCCGACGGTGGATGCTCCGGGGGCGCCTATGACATCATAATATGTGATGAATGCCACTCA
ACTGACTCGACTACCATCTTGGGCATCGGCACAGTCCTGGATCAGGCAGAGACGGCTGGA
GCGCGGCTCGTCGTGCTCGCCACCGCCACGCCTCCGGGATCGATCACCGTGCCACACCCC
AACATCGAGGAAGTGGCCCTGTCCAACACTGGAGAGATTCCCTTCTATGGCAAAGCCATC
CCCATTGAGGCCATCAAGGGGGGAAGGCATCTCATCTTCTGCCATTCCAAGAAGAAGTGT
GACGAGCTCGCCGCAAAGCTGACAGGCCTCGGACTCAATGCTGTAGCGTATTACCGGGGT
CTCGATGTGTCCGTCATACCGACTAGCGGAGACGTCGTTGTCGTGGCAACAGACGCTCTA
ATGACGGGTTTTACCGGCGACTTTGACTCAGTGATCGACTGCAACACATGTGTCACCCAG
ACAGTCGATTTCAGCTTGGATCCCACCTTCACCATTGAGACGACAACGCTGCCCCAAGAC
GCGGTGTCGCGTGCGCAGCGGCGAGGTAGGACTGGCAGGGGCAGGAGTGGCATCTACAGG
TTTGTGACTCCAGGAGAACGGCCCTCAGGCATGTTCGACTCCTCGGTCCTGTGTGAGTGC
TATGACGCAGGCTGCGCTTGGTATGAGCTCACGCCCGCTGAGACCTCGGTTAGGTTGCGG
GCTTACCTAAATACACCAGGGTTGCCCGTCTGCCAGGACCACCTAGAGTTCTGGGAGAGC
GTCTTCACAGGCCTCACCCACATAGATGCCCACTTCTTGTCCCAGACCAAACAGGCAGGA
GACAACCTCCCCTACCTGGTAGCATACCAAGCCACAGTGTGCGCCAGGGCTCAGGCTCCA
CCTCCATCGTGGGACCAAATGTGGAAGTGTCTCATACGGCTAAAGCCCACACTGCATGGG
CCAACGCCCCTGCTGTACAGGCTAGGAGCCGTTCAAAATGAGGTCACTCTCACACACCCC
ATAACCAAATACATCATGGCATGCATGTCGGCTGACCTGGAGGTCGTCACTAGCACCTGG
GTGCTAGTAGGCGGAGTCCTTGCGGCTCTGGCCGCGTACTGCCTGACGACAGGCAGCGTG
GTCATTGTGGGCAGGATCATCTTGTCCGGGAGGCCAGCTGTTATTCCCGACAGGGAAGTC
CTCTACCAGGAGTTCGATGAGATGGAAGAGTGTGCTTCACACCTCCCTTACATCGAGCAA
GGAATGCAGCTCGCCGAGCAATTCAAACAGAAGGCGCTCGGATTGCTGCAAACAGCCACC
AAGCAAGCGGAGGCTGCTGCTCCCGTGGTGGAGTCCAAGTGGCGAGCCCTTGAGGTCTTC
TGGGCGAAACACATGTGGAACTTCATCAGCGGGATACAGTACTTGGCAGGCCTATCCACT
CTGCCTGGAAACCCCGCGATAGCATCATTGATGGCTTTTACAGCCTCTATCACCAGCCCG
CTCACCACCCAAAATACCCTCCTGTTTAACATCTTGGGGGGATGGGTGGCTGCCCAACTC
GCTCCCCCCAGCGCTGCTTCGGCTTTCGTGGGCGCCGGCATTGCCGGTGCGGCCGTTGGC
AGCATAGGTCTCGGGAAGGTACTTGTGGACATTCTGGCGGGCTATGGGGCGGGGGTGGCT
GGCGCACTCGTGGCCTTTAAGGTCATGAGCGGCGAGATGCCCTCCACTGAGGATCTGGTT
AATTTACTCCCTGCCATCCTTTCTCCTGGCGCCCTGGTTGTCGGGGTCGTGTGCGCAGCA
ATACTGCGTCGGCACGTGGGCCCGGGAGAGGGGGCTGTGCAGTGGATGAACCGGCTGATA
GCGTTCGCTTCGCGGGGTAACCACGTCTCCCCCACGCACTATGTGCCCGAGAGCGACGCC
GCGGCGCGTGTTACTCAGATCCTCTCCAGCCTTACCATCACTCAGTTGCTGAAGAGGCTT
CATCAGTGGATTAATGAGGACTGCTCCACGCCTTGTTCCGGCTCGTGGCTAAAGGATGTT
TGGGACTGGATATGCACGGTGTTGAGTGACTTCAAGACTTGGCTCCAGTCCAAGCTCCTG
CCGCGGTTACCGGGACTCCCTTTCCTGTCATGCCAACGCGGGTACAAGGGAGTCTGGCGG
GGGGATGGCATCATGCAAACCACCTGCCCATGTGGAGCACAGATCACCGGACATGTCAAA
AATGGCTCCATGAGGATTGTTGGGCCAAAAACCTGCAGCAACACGTGGCATGGAACATTC
CCCATCAACGCATACACCACGGGCCCCTGCACGCCCTCCCCAGCGCCGAACTATTCCAGG
GCGCTGTGGCGGGTGGCTGCTGAGGAGTACGTGGAGGTTACGCGGGTGGGGGATTTCCAC
TACGTGACGGGCATGACCACTGACAACGTGAAATGCCCATGCCAGGTTCCAGCCCCTGAA
TTTTTCACGGAGGTGGATGGAGTACGGTTGCACAGGTATGCTCCAGTGTGCAAACCTCTC
CTACGAGAGGAGGTCGTATTCCAGGTCGGGCTCAACCAGTACCTGGTCGGGTCACAGCTC
CCATGTGAGCCCGAACCGGATGTGGCAGTGCTCACTTCCATGCTCACCGACCCCTCTCAT
ATTACAGCAGAGACGGCCAAGCGTAGGCTGGCCAGGGGGTCTCCCCCCTCCTTGGCCAGC
TCTTCAGCTAGCCAGTTGTCTGCGCCTTCTTTGAAGGCGACATGTACTACCCATCATGAC
TCCCCGGACGCTGACCTCATCGAGGCCAACCTCCTGTGGCGGCAGGAGATGGGCGGGAAC
ATCACCCGTGTGGAGTCAGAAAATAAGGTGGTAATCCTGGACTCTTTCGATCCGATTCGG
GCGGTGGAGGATGAGAGGGAAATATCCGTCCCGGCGGAGATCCTGCGAAAACCCAGGAAG
TTCCCCCCAGCGTTGCCCATATGGGCACGCCCGGATTACAACCCTCCACTGCTAGAGTCC
TGGAAGGACCCGGACTACGTCCCCCCGGTGGTACACGGGTGCCCTTTGCCATCTACCAAG
GCCCCCCCAATACCACCTCCACGGAGGAAGAGGACGGTTGTCCTGACAGAGTCCACCGTG
TCTTCTGCCTTGGCGGAGCTCGCTACTAAGACCTTTGGCAGCTCCGGGTCGTCGGCCGTT
GACAGCGGCACGGCGACTGGCCCTCCCGATCAGGCCTCCGACGACGGCGACAAAGGATCC
GACGTTGAGTCGTACTCCTCCATGCCCCCCCTCGAGGGAGAGCCAGGGGACCCCGACCTC
AGCGACGGGTCTTGGTCTACCGTGAGCGGGGAAGCTGGTGAGGACGTCGTCTGCTGCTCA
ATGTCCTATACATGGACAGGTGCCTTGATCACGCCATGCGCTGCGGAGGAGAGCAAGTTG
CCCATCAATCCGTTGAGCAACTCTTTGCTGCGTCACCACAGTATGGTCTACTCCACAACA
TCTCGCAGCGCAAGTCTGCGGCAGAAGAAGGTCACCTTTGACAGACTGCAAGTCCTGGAC
GACCACTACCGGGACGTGCTCAAGGAGATGAAGGCGAAGGCGTCCACAGTTAAGGCTAGG
CTTCTATCTATAGAGGAGGCCTGCAAACTGACGCCCCCACATTCGGCCAAATCCAAATTT
GGCTACGGGGCGAAGGACGTCCGGAGCCTATCCAGCAGGGCCGTCAACCACATCCGCTCC
GTGTGGGAGGACTTGCTGGAAGACACTGAAACACCAATTGATACCACCATCATGGCAAAA
AATGAGGTTTTCTGCGTCCAACCAGAGAAAGGAGGCCGCAAGCCAGCTCGCCTTATCGTA
TTCCCAGACCTGGGGGTACGTGTATGCGAGAAGATGGCCCTTTACGACGTGGTCTCCACC
CTTCCTCAGGCCGTGATGGGCCCCTCATACGGATTCCAGTACTCTCCTGGGCAGCGGGTC
GAGTTCCTGGTGAATACCTGGAAATCAAAGAAATGCCCTATGGGCTTCTCATATGACACC
CGCTGCTTTGACTCAACGGTCACTGAGAATGACATCCGTACTGAGGAATCAATTTACCAA
TGTTGTGACTTGGCCCCCGAAGCCAGGCAGGCCATAAGGTCGCTCACAGAGCGGCTTTAT
GTCGGGGGTCCCCTGACTAATTCGAAGGGGCAGAACTGCGGTTATCGCCGGTGCCGCGCA
AGTGGCGTGCTGACGACTAGCTGCGGCAACACCCTCACATGTTACTTGAAGGCCACTGCG
GCCTGTCGAGCTGCAAAGCTCCAGGACTGCACGATGCTCGTGAACGGAGACGACCTTGTC
GTTATCTGTGAGAGTGCGGGAACCCAGGAGGATGCGGCGGCCCTACGAGCCTTCACGGAG
GCTATGACTAGGTATTCCGCCCCCCCCGGGGACCCGCCCCAACCAGAATACGACTTGGAG
CTGATAACGTCATGCTCCTCCAATGTGTCGGTCGCGCACGATGCATCCGGCAAAAGGGTG
TACTACCTCACCCGTGACCCCACCACCCCCCTCGCACGGGCTGCGTGGGAGACAGTTAGA
CACACTCCAGTCAACTCCTGGCTAGGCAATATCATCATGTATGCGCCCACCCTATGGGCG
AGGATGATTCTGATGACTCATTTCTTCTCTATCCTTCTAGCTCAGGAGCAACTTGAAAAA
GCCCTGGATTGTCAGATCTACGGGGCCTGTTACTCCATTGAGCCACTTGACCTACCTCAG
ATCATTGAACGACTCCATGGTCTTAGCGCATTTTCACTCCACAGTTACTCTCCAGGTGAG
ATCAATAGGGTGGCTTCATGCCTCAGGAAACTTGGGGTACCGCCTTTGCGAGTCTGGAGA
CATCGGGCCAGAAGTGTCCGCGCTAAGCTACTGTCCCAGGGGGGGAGGGCTGCCACTTGC
GGCAAGTACCTCTTCAACTGGGCAGTAAAGACCAAGCTTAAACTCACTCCAATCCCGGCT
GCGTCCCAGCTAGACTTGTCCGGCTGGTTCGTTGCTGGTTACAACGGGGGAGACATATAT
CACAGCCTGTCTCGTGCCCGACCCCGTTGGTTCATGTTGTGCCTACTCCTACTTTCTGTA
GGGGTAGGCATCTACCTGCTCCCCAACCGGTGA

# Drug_Target_2_General_Function:
Involved in structural molecule activity

# Drug_Target_2_General_References:
10702283	Di Marco S, Rizzi M, Volpari C, Walsh MA, Narjes F, Colarusso S, De Francesco R, Matassa VG, Sollazzo M: Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem. 2000 Mar 10;275(10):7152-7.
12560074	Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MP, Rowlands DJ: The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. 2003 Jan 30;535(1-3):34-8.
1849488	Kato N, Hijikata M, Nakagawa M, Ootsuyama Y, Muraiso K, Ohkoshi S, Shimotohno K: Molecular structure of the Japanese hepatitis C viral genome. FEBS Lett. 1991 Mar 25;280(2):325-8.
2175903	Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K: Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9524-8.
7999043	Kaneko T, Tanji Y, Satoh S, Hijikata M, Asabe S, Kimura K, Shimotohno K: Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun. 1994 Nov 30;205(1):320-6.
8392606	Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K: Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol. 1993 Aug;67(8):4665-75.
8531962	Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996 Jan 11;334(2):77-81.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2297

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
327024

# Drug_Target_2_Name:
Genome polyprotein

# Drug_Target_2_Number_of_Residues:
3010

# Drug_Target_2_PDB_ID:
1CU1

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00271	Helicase_C
PF00998	RdRP_3
PF01001	HCV_NS4b
PF01006	HCV_NS4a
PF01506	HCV_NS5a
PF01538	HCV_NS2
PF01539	HCV_env
PF01542	HCV_core
PF01543	HCV_capsid
PF01560	HCV_NS1
PF02907	Peptidase_S29
PF08300	HCV_NS5a_1a
PF08301	HCV_NS5a_1b

# Drug_Target_2_Protein_Sequence:
>Genome polyprotein [Contains: Core protein p21
MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSERSQPRG
RRQPIPKARRPEGRTWAQPGYPWPLYGNEGMGWAGWLLSPRGSRPSWGPTDPRRRSRNLG
KVIDTLTCGFADLMGYIPLVGAPLGGAARALAHGVRVLEDGVNYATGNLPGCSFSIFLLA
LLSCLTIPASAYEVRNVSGIYHVTNDCSNSSIVYEAADMIMHTPGCVPCVRESNFSRCWV
ALTPTLAARNSSIPTTTIRRHVDLLVGAAALCSAMYVGDLCGSVFLVSQLFTFSPRRYET
VQDCNCSIYPGHVSGHRMAWDMMMNWSPTTALVVSQLLRIPQAVVDMVAGAHWGVLAGLA
YYSMVGNWAKVLIVMLLFAGVDGHTHVTGGRVASSTQSLVSWLSQGPSQKIQLVNTNGSW
HINRTALNCNDSLQTGFIAALFYAHRFNASGCPERMASCRPIDEFAQGWGPITHDMPESS
DQRPYCWHYAPRPCGIVPASQVCGPVYCFTPSPVVVGTTDRFGAPTYSWGENETDVLLLS
NTRPPQGNWFGCTWMNSTGFTKTCGGPPCNIGGVGNNTLVCPTDCFRKHPEATYTKCGSG
PWLTPRCMVDYPYRLWHYPCTVNFTVFKVRMYVGGVEHRLNAACNWTRGERCDLEDRDRS
ELSPLLLSTTEWQILPCSFTTLPALSTGLIHLHRNIVDVQYLYGIGSAVVSFAIKWEYIL
LLFLLLADARVCACLWMMLLIAQAEATLENLVVLNAASVAGAHGLLSFLVFFCAAWYIKG
RLVPGAAYALYGVWPLLLLLLALPPRAYAMDREMAASCGGAVFVGLVLLTLSPYYKVFLA
RLIWWLQYFITRAEAHLQVWVPPLNVRGGRDAIILLTCAVHPELIFDITKLLLAILGPLM
VLQAGITRVPYFVRAQGLIRACMLVRKVAGGHYVQMAFMKLAALTGTYVYDHLTPLRDWA
HAGLRDLAVAVEPVVFSDMETKLITWGADTAACGDIISGLPVSARRGKEILLGPADSFGE
QGWRLLAPITAYSQQTRGLLGCIITSLTGRDKNQVDGEVQVLSTATQSFLATCVNGVCWT
VYHGAGSKTLAGPKGPITQMYTNVDQDLVGWPAPPGARSMTPCTCGSSDLYLVTRHADVV
PVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPSGHVVGIFRAAVCTRGVAKAVDFIPVES
METTMRSPVFTDNSSPPAVPQTFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAA
TLGFGAYMSKAHGIEPNIRTGVRTITTGGPITYSTYCKFLADGGCSGGAYDIIICDECHS
TDSTTILGIGTVLDQAETAGARLVVLATATPPGSITVPHPNIEEVALSNTGEIPFYGKAI
PIEAIKGGRHLIFCHSKKKCDELAAKLTGLGLNAVAYYRGLDVSVIPTSGDVVVVATDAL
MTGFTGDFDSVIDCNTCVTQTVDFSLDPTFTIETTTLPQDAVSRAQRRGRTGRGRSGIYR
FVTPGERPSGMFDSSVLCECYDAGCAWYELTPAETSVRLRAYLNTPGLPVCQDHLEFWES
VFTGLTHIDAHFLSQTKQAGDNLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHG
PTPLLYRLGAVQNEVTLTHPITKYIMACMSADLEVVTSTWVLVGGVLAALAAYCLTTGSV
VIVGRIILSGRPAVIPDREVLYQEFDEMEECASHLPYIEQGMQLAEQFKQKALGLLQTAT
KQAEAAAPVVESKWRALEVFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTASITSP
LTTQNTLLFNILGGWVAAQLAPPSAASAFVGAGIAGAAVGSIGLGKVLVDILAGYGAGVA
GALVAFKVMSGEMPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLI
AFASRGNHVSPTHYVPESDAAARVTQILSSLTITQLLKRLHQWINEDCSTPCSGSWLKDV
WDWICTVLSDFKTWLQSKLLPRLPGLPFLSCQRGYKGVWRGDGIMQTTCPCGAQITGHVK
NGSMRIVGPKTCSNTWHGTFPINAYTTGPCTPSPAPNYSRALWRVAAEEYVEVTRVGDFH
YVTGMTTDNVKCPCQVPAPEFFTEVDGVRLHRYAPVCKPLLREEVVFQVGLNQYLVGSQL
PCEPEPDVAVLTSMLTDPSHITAETAKRRLARGSPPSLASSSASQLSAPSLKATCTTHHD
SPDADLIEANLLWRQEMGGNITRVESENKVVILDSFDPIRAVEDEREISVPAEILRKPRK
FPPALPIWARPDYNPPLLESWKDPDYVPPVVHGCPLPSTKAPPIPPPRRKRTVVLTESTV
SSALAELATKTFGSSGSSAVDSGTATGPPDQASDDGDKGSDVESYSSMPPLEGEPGDPDL
SDGSWSTVSGEAGEDVVCCSMSYTWTGALITPCAAEESKLPINPLSNSLLRHHSMVYSTT
SRSASLRQKKVTFDRLQVLDDHYRDVLKEMKAKASTVKARLLSIEEACKLTPPHSAKSKF
GYGAKDVRSLSSRAVNHIRSVWEDLLEDTETPIDTTIMAKNEVFCVQPEKGGRKPARLIV
FPDLGVRVCEKMALYDVVSTLPQAVMGPSYGFQYSPGQRVEFLVNTWKSKKCPMGFSYDT
RCFDSTVTENDIRTEESIYQCCDLAPEARQAIRSLTERLYVGGPLTNSKGQNCGYRRCRA
SGVLTTSCGNTLTCYLKATAACRAAKLQDCTMLVNGDDLVVICESAGTQEDAAALRAFTE
AMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWETVR
HTPVNSWLGNIIMYAPTLWARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQ
IIERLHGLSAFSLHSYSPGEINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAATC
GKYLFNWAVKTKLKLTPIPAASQLDLSGWFVAGYNGGDIYHSLSRARPRWFMLCLLLLSV
GVGIYLLPNR

# Drug_Target_2_Reaction:
nucleoside triphosphate + RNAn = diphosphate + RNAn+1

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
NS5B is a RNA-dependent RNA polymerase that plays an essential role in the virus replication

# Drug_Target_2_SwissProt_ID:
P26662

# Drug_Target_2_SwissProt_Name:
POLG_HCVJA

# Drug_Target_2_Synonyms:
Capsid protein C
Core protein p19
EC 2.7.7.48
EC 3.4.21.98
EC 3.4.22.-
EC 3.6.1.-
EC 3.6.1.15
Envelope glycoprotein E1
Envelope glycoprotein E2
Genome polyprotein [Contains: Core protein p21
Hepacivirin
NS1
NS3P
NS4A
NS4B
NS5A
NS5B
Non-structural protein 4A
Non-structural protein 4B
Non-structural protein 5A
Protease NS2-3
RNA-directed RNA polymerase
Serine protease/NTPase/helicase NS3
gp32
gp35
gp68
gp70
p21
p23
p27
p56
p68]
p7
p70
p8

# Drug_Target_2_Theoretical_pI:
8.07

# Drug_Target_2_Transmembrane_Regions:
169-189
359-379
726-746
758-778
783-803
814-834
882-902
929-949
1658-1678
1806-1826
1829-1849
1851-1871
1882-1902
2990-3010

# Drug_Target_3_Cellular_Location:
Core protein p21:Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
M58335

# Drug_Target_3_GenBank_ID_Protein:
329771

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
Not Available

# Drug_Target_3_Gene_Sequence:
>9033 bp
ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCACAG
GACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGCGCAGG
GGCCCCAGGTTGGGTGTGCGCGCGCCCAGGAAGACTTCCGAGCGGTCGCAACCTCGTGGA
AGGCGACAACCTATCCCCAAGGCTCGCCGGCCCGAGGGCAGGACCTGGGCTCAGCCCGGG
TACCCTTGGCCTCTCTATGGCAATGAGGGCTTAGGGTGGGCAGGATGGCTCCTGTCACCC
CGCGGCTCCCGGCCTAGTTGGGGCCCCACGGACCCCCGGCGTAGGTCGCGTAATTTGGGT
AAGGTCATCGATACCCTCACATGCGGCTTCGCCGATCTCATGGGGTACATTCCGCTCGTC
GGCGCCCCCCTGGGGGGCGCTGCCAGGGCCCTGGCACATGGTGTCCGGGTTCTGGAGGAC
GGCGTGAACTATGCAACAGGGAATCTGCCCGGTTGCTCTTTTTCTATCTTCCTCTTGGCT
CTGCTGTCCTGCCTGACCACCCCAGCTTCCGCTTACGAAGTGCACAACGTGTCCGGGATA
TATCATGTCACGAACGACTGCTCCAACGCAAGCATTGTGTATGAGGCAGCGGACTTGATC
ATGCATACTCCTGGGTGCGTGCCCTGCGTTCGGGAAGGCAACTCCTCCCGCTGCTGGGTA
GCGCTCACTCCCACGCTCGCAGCCAGGAACGTCACCATCCCCACCACGACGATACGACGC
CACGTCGATCTGCTCGTTGGGGCGGCTGCTTTCTGTTCCGCTATGTACGTGGGGGACCTC
TGCGGATCTGTTTTCCTCGTCTCTCAGCTGTTCACCTTCTCGCCTCGCCGGCATGTGACA
TTACAGGACTGTAACTGCTCAATTTATCCCGGCCATGTGTCGGGTCACCGTATGGCTTGG
GACATGATGATGAACTGGTCGCCCACAACAGCCCTAGTGGTGTCGCAGTTACTCCGGATC
CCACAAGCCGTCGTGGACATGGTGGCGGGGGCCCACTGGGGAGTCCTGGCGGGCCTTGCC
TACTATTCCATGGCGGGGAACTGGGCTAAGGTTCTGATTGTGATGCTACTTTTTGCTGGC
GTTGACGGGGATACCCACGTGACAGGGGGGGCGCAAGCCAAAACCACCAACAGGCTCGTG
TCCATGTTCGCAAGTGGGCCGTCTCAGAAAATCCAGCTTATAAACACCAATGGGAGTTGG
CACATCAACAGGACTGCCCTGAACTGCAATGACTCTCTCCAGACTGGGTTTCTTGCCGCG
CTGTTCTACACACATAGTTTCAACTCGTCCGGGTGCCCAGAGCGCATGGCCCAGTGCCGC
ACCATTGACAAGTTCGACCAGGGATGGGGTCCCATTACTTATGCTGAGTCTAGCAGATCA
GACCAGAGGCCATATTGCTGGCACTACCCACCTCCACAATGTACCATCGTACCTGCGTCG
GAGGTGTGCGGCCCAGTGTACTGCTTCACCCCAAGCCCTGTCGTCGTGGGGACGACCGAT
CGTTTCGGTGTCCCTACGTATAGATGGGGGGAGAACGAGACTGACGTGCTGCTGCTCAAC
AACACGCGGCCGCCGCAAGGCAACTGGTTCGGCTGCACATGGATGAATAGCACCGGGTTC
ACCAAGACATGTGGGGGGCCCCCGTGTAACATCGGGGGGGTCGGCAACAACACCCTGACC
TGCCCCACGGACTGCTTCCGGAAGCACCCCGAGGCTACCTACACAAAATGTGGTTCGGGG
CCTTGGCTGACACCTAGGTGCATGGTTGACTATCCATACAGGCTCTGGCATTACCCCTGC
ACTGTTAACTTTACCATCTTCAAGGTTAGGATGTATGTGGGGGGGGTGGAGCACAGGCTC
AATGCTGCATGCAATTGGACCCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGGCCG
GAGCTCAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGGTACTGCCCTGTTCCTTCACC
ACCCTACCAGCTCTGTCCACTGGCTTGATTCACCTCCATCAGAACATCGTGGACGTGCAA
TACCTATACGGTATAGGGTCAGCGGTTGTCTCCTTTGCAATCAAATGGGAGTATGTCCTG
TTGCTTTTCCTTCTCCTAGCGGACGCACGTGTCTGTGCCTGCTTGTGGATGATGCTGCTG
ATAGCCCAGGCCGAGGCCGCCTTGGAGAACCTGGTGGTCCTCAATTCGGCGTCTGTGGCC
GGCGCACATGGCATCCTCTCCTTCCTTGTGTTCTTCTGTGCCGCCTGGTACATCAAAGGC
AGGCTGGTCCCTGGGGCGACATATGCTCTTTATGGCGTGTGGCCGCTGCTCCTGCTCTTG
CTGGCATTACCACCGCGAGCTTACGCCATGGACCGGGAGATGGCTGCATCGTGCGGAGGC
GCGGTTTTTGTGGGTCTGGTACTCCTGACTTTGTCACCATACTACAAGGTGTTCCTCGCT
AGGCTCATATGGTGGTTACAATATTTTACCACCAGAGCCGAGGCGGACTTACATGTGTGG
ATCCCCCCCCTCAACGCTCGGGGAGGCCGCGATGCCATCATCCTCCTCATGTGCGCAGTC
CATCCAGAGCTAATCTTTGACATCACCAAACTTCTAATTGCCATACTCGGTCCGCTCATG
GTGCTCCAAGCTGGCATAACCAGAGTGCCGTACTTCGTGCGCGCTCAAGGGCTCATTCAT
GCATGCATGTTAGTGCGGAAGGTCGCTGGGGGTCATTATGTCCAAATGGCCTTCATGAAG
CTGGGCGCGCTGACAGGCACGTACATTTACAACCATCTTACCCCGCTACGGGATTGGCCA
CGCGCGGGCCTACGAGACCTTGCGGTGGCAGTGGAGCCCGTCGTCTTCTCCGACATGGAG
ACCAAGATCATCACCTGGGGAGCAGACACCGCGGCGTGTGGGGACATCATCTTGGGTCTG
CCCGTCTCCGCCCGAAGGGGAAAGGAGATACTCCTGGGCCCGGCCGATAGTCTTGAAGGG
CGGGGGTTGCGACTCCTCGCGCCCATCACGGCCTACTCCCAACAGACGCGGGGCCTACTT
GGTTGCATCATCACTAGCCTTACAGGCCGGGACAAGAACCAGGTCGAGGGAGAGGTTCAG
GTGGTTTCCACCGCAACACAATCCTTCCTGGCGACCTGCGTCAACGGCGTGTGTTGGACC
GTTTACCATGGTGCTGGCTCAAAGACCTTAGCCGCGCCAAAGGGGCCAATCACCCAGATG
TACACTAATGTGGACCAGGACCTCGTCGGCTGGCCCAAGCCCCCCGGGGCGCGTTCCTTG
ACACCATGCACCTGTGGCAGCTCAGACCTTTACTTGGTCACGAGACATGCTGACGTCATT
CCGGTGCGCCGGCGGGGCGACAGTAGGGGGAGCCTGCTCTCCCCCAGGCCTGTCTCCTAC
TTGAAGGGCTCTTCGGGTGGTCCACTGCTCTGCCCCTTCGGGCACGCTGTGGGCATCTTC
CGGGCTGCCGTATGCACCCGGGGGGTTGCGAAGGCGGTGGACTTTGTGCCCGTAGAGTCC
ATGGAAACTACTATGCGGTCTCCGGTCTTCACGGACAACTCATCCCCCCCGGCCGTACCG
CAGTCATTTCAAGTGGCCCACCTACACGCTCCCACTGGCAGCGGCAAGAGTACTAAAGTG
CCGGCTGCATATGCAGCCCAAGGGTACAAGGTGCTCGTCCTCAATCCGTCCGTTGCCGCT
ACCTTAGGGTTTGGGGCGTATATGTCTAAGGCACACGGTATTGACCCCAACATCAGAACT
GGGGTAAGGACCATTACCACAGGCGCCCCCGTCACATACTCTACCTATGGCAAGTTTCTT
GCCGATGGTGGTTGCTCTGGGGGCGCTTATGACATCATAATATGTGATGAGTGCCATTCA
ACTGACTCGACTACAATCTTGGGCATCGGCACAGTCCTGGACCAAGCGGAGACGGCTGGA
GCGCGGCTTGTCGTGCTCGCCACCGCTACGCCTCCGGGATCGGTCACCGTGCCACACCCA
AACATCGAGGAGGTGGCCCTGTCTAATACTGGAGAGATCCCCTTCTATGGCAAAGCCATC
CCCATTGAAGCCATCAGGGGGGGAAGGCATCTCATTTTCTGTCATTCCAAGAAGAAGTGC
GACGAGCTCGCCGCAAAGCTGTCAGGCCTCGGAATCAACGCTGTGGCGTATTACCGGGGG
CTCGATGTGTCCGTCATACCAACTATCGGAGACGTCGTTGTCGTGGCAACAGACGCTCTG
ATGACGGGCTATACGGGCGACTTTGACTCAGTGATCGACTGTAACACATGTGTCACCCAG
ACAGTCGACTTCAGCTTGGATCCCACCTTCACCATTGAGACGACGACCGTGCCTCAAGAC
GCAGTGTCGCGCTCGCAGCGGCGGGGTAGGACTGGCAGGGGTAGGAGAGGCATCTACAGG
TTTGTGACTCCGGGAGAACGGCCCTCGGGCATGTTCGATTCCTCGGTCCTGTGTGAGTGC
TATGACGCGGGCTGTGCTTGGTACGAGCTCACCCCGGCCGAGACCTCGGTTAGGTTGCGG
GCCTACCTGAACACACCAGGGTTGCCCGTTTGCCAGGACCACCTGGAGTTCTGGGAGAGT
GTCTTCACAGGCCTCACCCATATAGATGCACACTTCTTGTCCCAGACCAAGCAGGCAGGA
GACAACTTCCCCTACCTGGTAGCATACCAAGCCACGGTGTGCGCCAGGGCTCAGGCCCCA
CCTCCATCATGGGATCAAATGTGGAAGTGTCTCATACGGCTGAAACCTACGCTGCACGGG
CCAACACCCTTGCTGTACAGGCTGGGAGCCGTCCAGAATGAGGTCACCCTCACCCACCCC
ATAACCAAATACATCATGGCATGCATGTCGGCTGACCTGGAGGTCGTCACTAGCACCTGG
GTGCTGGTGGGCGGAGTCCTTGCAGCTCTGGCCGCGTATTGCCTGACAACAGGCAGTGTG
GTCATTGTGGGTAGGATTATCTTGTCCGGGAGGCCGGCCATTGTTCCCGACAGGGAGCTT
CTCTACCAGGAGTTCGATGAAATGGAAGAGTGCGCCTCGCACCTCCCTTACATCGAGCAG
GGAATGCAGCTCGCCGAGCAATTCAAGCAGAAAGCGCTCGGGTTACTGCAAACAGCCACC
AAACAAGCGGAGGCTGCTGCTCCCGTGGTGGAGTCCAAGTGGCGAGCCCTTGAGACATTC
TGGGCGAAGCACATGTGGAATTTCATCAGCGGGATACAGTACTTAGCAGGCTTATCCACT
CTGCCTGGGAACCCCGCAATAGCATCATTGATGGCATTCACAGCCTCTATCACCAGCCCG
CTCACCACCCAAAGTACCCTCCTGTTTAACATCTTGGGGGGGTGGGTGGCTGCCCAACTC
GCCCCCCCCAGCGCCGCTTCGGCTTTCGTGGGCGCCGGCATCGCCGGTGCGGCTGTTGGC
AGCATAGGCCTTGGGAAGGTGCTTGTGGACATTCTGGCGGGTTATGGAGCAGGAGTGGCC
GGCGCGCTCGTGGCCTTTAAGGTCATGAGCGGCGAGATGCCCTCCACCGAGGACCTGGTC
AATCTACTTCCTGCCATCCTCTCTCCTGGCGCCCTGGTCGTCGGGGTCGTGTGTGCAGCA
ATACTGCGTCGACACGTGGGTCCGGGAGAGGGGGCTGTGCAGTGGATGAACCGGCTGATA
GCGTTCGCCTCGCGGGGTAATCATGTTTCCCCCACGCACTATGTGCCTGAGAGCGACGCC
GCAGCGCGTGTTACTCAGATCCTCTCCAGCCTTACCATCACTCAGCTGCTGAAAAGGCTC
CACCAGTGGATTAATGAAGACTGCTCCACACCGTGTTCCGGCTCGTGGCTAAGGGATGTT
TGGGACTGGATATGCACGGTGTTGACTGACTTCAAGACCTGGCTCCAGTCCAAGCTCCTG
CCGCAGCTACCTGGAGTCCCTTTTTTCTCGTGCCAACGCGGGTACAAGGGAGTCTGGCGG
GGAGACGGCATCATGCAAACCACCTGCCCATGTGGAGCACAGATCACCGGACATGTCAAA
AACGGTTCCATGAGGATCGTCGGGCCTAAGACCTGCAGCAACACGTGGCATGGAACATTC
CCCATCAACGCATACACCACGGGCCCCTGCACACCCTCTCCAGCGCCAAACTATTCTAGG
GCGCTGTGGCGGGTGGCCGCTGAGGAGTACGTGGAGGTCACGCGGGTGGGGGATTTCCAC
TACGTGACGGGCATGACCACTGACAACGTAAAGTGCCCATGCCAGGTTCCGGCTCCTGAA
TTCTTCTCGGAGGTGGACGGAGTGCGGTTGCACAGGTACGCTCCGGCGTGCAGGCCTCTC
CTACGGGAGGAGGTTACATTCCAGGTCGGGCTCAACCAATACCTGGTTGGGTCACAGCTA
CCATGCGAGCCCGAACCGGATGTAGCAGTGCTCACTTCCATGCTCACCGACCCCTCCCAC
ATCACAGCAGAAACGGCTAAGCGTAGGTTGGCCAGGGGGTCTCCCCCCTCCTTGGCCAGC
TCTTCAGCTAGCCAGTTGTCTGCGCCTTCCTTGAAGGCGACATGCACTACCCACCATGTC
TCTCCGGACGCTGACCTCATCGAGGCCAACCTCCTGTGGCGGCAGGAGATGGGCGGGAAC
ATCACCCGCGTGGAGTCGGAGAACAAGGTGGTAGTCCTGGACTCTTTCGACCCGCTTCGA
GCGGAGGAGGATGAGAGGGAAGTATCCGTTCCGGCGGAGATCCTGCGGAAATCCAAGAAG
TTCCCCGCAGCGATGCCCATCTGGGCGCGCCCGGATTACAACCCTCCACTGTTAGAGTCC
TGGAAGGACCCGGACTACGTCCCTCCGGTGGTGCACGGGTGCCCGTTGCCACCTATCAAG
GCCCCTCCAATACCACCTCCACGGAGAAAGAGGACGGTTGTCCTAACAGAGTCCTCCGTG
TCTTCTGCCTTAGCGGAGCTCGCTACTAAGACCTTCGGCAGCTCCGAATCATCGGCCGTC
GACAGCGGCACGGCGACCGCCCTTCCTGACCAGGCCTCCGACGACGGTGACAAAGGATCC
GACGTTGAGTCGTACTCCTCCATGCCCCCCCTTGAGGGGGAACCGGGGGACCCCGATCTC
AGTGACGGGTCTTGGTCTACCGTGAGCGAGGAAGCTAGTGAGGATGTCGTCTGCTGCTCA
ATGTCCTACACATGGACAGGCGCCTTGATCACGCCATGCGCTGCGGAGGAAAGCAAGCTG
CCCATCAACGCGTTGAGCAACTCTTTGCTGCGCCACCATAACATGGTTTATGCCACAACA
TCTCGCAGCGCAGGCCTGCGGCAGAAGAAGGTCACCTTTGACAGACTGCAAGTCCTGGAC
GACCACTACCGGGACGTGCTCAAGGAGATGAAGGCGAAGGCGTCCACAGTTAAGGCTAAA
CTCCTATCCGTAGAGGAAGCCTGCAAGCTGACGCCCCCACATTCGGCCAAATCCAAGTTT
GGCTATGGGGCAAAGGACGTCCGGAACCTATCCAGCAAGGCCGTTAACCACATCCACTCC
GTGTGGAAGGACTTGCTGGAAGACACTGTGACACCAATTGACACCACCATCATGGCAAAA
AATGAGGTTTTCTGTGTCCAACCAGAGAAAGGAGGCCGTAAGCCAGCCCGCCTTATCGTA
TTCCCAGATCTGGGAGTCCGTGTATGCGAGAAGATGGCCCTCTATGATGTGGTCTCCACC
CTTCCTCAGGTCGTGATGGGCTCCTCATACGGATTCCAGTACTCTCCTGGGCAGCGAGTC
GAGTTCCTGGTGAATACCTGGAAATCAAAGAAAAACCCCATGGGCTTTTCATATGACACT
CGCTGTTTCGACTCAACGGTCACCGAGAACGACATCCGTGTTGAGGAGTCAATTTACCAA
TGTTGTGACTTGGCCCCCGAAGCCAGACAGGCCATAAAATCGCTCACAGAGCGGCTTTAT
ATCGGGGGTCCTCTGACTAATTCAAAAGGGCAGAACTGCGGTTATCGCCGGTGCCGCGCG
AGCGGCGTGCTGACGACTAGCTGCGGTAACACCCTCACATGTTACTTGAAGGCCTCTGCA
GCCTGTCGAGCTGCGAAGCTCCAGGACTGCACGATGCTCGTGAACGGAGACGACCTCGTC
GTTATCTGTGAAAGCGCGGGAACCCAAGAGGACGCGGCGAGCCTACGAGTCTTCACGGAG
GCTATGACTAGGTACTCCGCCCCCCCCGGGGACCCGCCCCAACCAGAATACGACTTGGAG
CTGATAACATCATGTTCCTCCAATGTGTCGGTCGCCCACGATGCATCAGGCAAAAGGGTG
TACTACCTCACCCGTGATCCCACCACCCCCCTAGCACGGGCTGCGTGGGAGACAGCTAGA
CACACTCCAGTTAACTCCTGGCTAGGCAACATTATTATGTATGCGCCCACTTTGTGGGCA
AGGATGATTCTGATGACTCACTTCTTCTCCATCCTTCTAGCGCAGGAGCAACTTGAAAAA
GCCCTGGACTGCCAGATCTACGGGGCCTGTTACTCCATTGAGCCACTTGACCTACCTCAG
ATCATTGAACGACTCCATGGCCTTAGCGCATTTTCACTCCATAGTTACTCTCCAGGTGAG
ATCAATAGGGTGGCTTCATGCCTCAGGAAACTTGGGGTACCACCCTTGCGAGTCTGGAGA
CATCGGGCCAGGAGCGTCCGCGCTAGGCTACTGTCCCAGGGAGGGAGGGCCGCCACTTGT
GGCAAATACCTCTTCAACTGGGCAGTAAAAACCAAACTTAAACTCACTCCAATCCCGGCT
GCGTCCCGGCTGGACTTGTCCGGCTGGTTCGTTGCTGGTTACAGCGGGGGAGACATATAT
CACAGCCTGTCTCGTGCCCGACCCCGTTGGTTCATGCTGTGCCTACTCCTACTTTCTGTA
GGGGTAGGCATCTACCTGCTCCCCAACCGATGA

# Drug_Target_3_General_Function:
Involved in structural molecule activity

# Drug_Target_3_General_References:
10318918	Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG: NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5533-8.
10557268	Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13034-9.
10574797	Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC: Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure. 1999 Nov 15;7(11):1353-63.
10574802	Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure. 1999 Nov 15;7(11):1417-26.
11591719	Thibeault D, Maurice R, Pilote L, Lamarre D, Pause A: In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J Biol Chem. 2001 Dec 7;276(49):46678-84. Epub 2001 Oct 8.
12660945	Hofmann WP, Sarrazin C, Kronenberger B, Schonberger B, Bruch K, Zeuzem S: Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. J Infect Dis. 2003 Mar 15;187(6):982-7. Epub 2003 Mar 6.
1847440	Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, Andoh T, Yoshida I, Okayama H: Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol. 1991 Mar;65(3):1105-13.
8647104	Borowski P, Heiland M, Oehlmann K, Becker B, Kornetzky L, Feucht H, Laufs R: Non-structural protein 3 of hepatitis C virus inhibits phosphorylation mediated by cAMP-dependent protein kinase. Eur J Biochem. 1996 May 1;237(3):611-8.
8861916	Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z: The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 1996 Oct 18;87(2):331-42.
9568891	Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, De Francesco R, Kuo LC, Chen Z: Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 1998 Apr;7(4):837-47.
9614113	Cho HS, Ha NC, Kang LW, Chung KM, Back SH, Jang SK, Oh BH: Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA. J Biol Chem. 1998 Jun 12;273(24):15045-52.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2694

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
327196

# Drug_Target_3_Name:
Genome polyprotein

# Drug_Target_3_Number_of_Residues:
3010

# Drug_Target_3_PDB_ID:
1CU1

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00998	RdRP_3
PF01001	HCV_NS4b
PF01006	HCV_NS4a
PF01506	HCV_NS5a
PF01538	HCV_NS2
PF01539	HCV_env
PF01542	HCV_core
PF01543	HCV_capsid
PF01560	HCV_NS1
PF02907	Peptidase_S29
PF08300	HCV_NS5a_1a
PF08301	HCV_NS5a_1b

# Drug_Target_3_Protein_Sequence:
>Genome polyprotein [Contains: Core protein p21
MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRAPRKTSERSQPRG
RRQPIPKARRPEGRTWAQPGYPWPLYGNEGLGWAGWLLSPRGSRPSWGPTDPRRRSRNLG
KVIDTLTCGFADLMGYIPLVGAPLGGAARALAHGVRVLEDGVNYATGNLPGCSFSIFLLA
LLSCLTTPASAYEVHNVSGIYHVTNDCSNASIVYEAADLIMHTPGCVPCVREGNSSRCWV
ALTPTLAARNVTIPTTTIRRHVDLLVGAAAFCSAMYVGDLCGSVFLVSQLFTFSPRRHVT
LQDCNCSIYPGHVSGHRMAWDMMMNWSPTTALVVSQLLRIPQAVVDMVAGAHWGVLAGLA
YYSMAGNWAKVLIVMLLFAGVDGDTHVTGGAQAKTTNRLVSMFASGPSQKIQLINTNGSW
HINRTALNCNDSLQTGFLAALFYTHSFNSSGCPERMAQCRTIDKFDQGWGPITYAESSRS
DQRPYCWHYPPPQCTIVPASEVCGPVYCFTPSPVVVGTTDRFGVPTYRWGENETDVLLLN
NTRPPQGNWFGCTWMNSTGFTKTCGGPPCNIGGVGNNTLTCPTDCFRKHPEATYTKCGSG
PWLTPRCMVDYPYRLWHYPCTVNFTIFKVRMYVGGVEHRLNAACNWTRGERCDLEDRDRP
ELSPLLLSTTEWQVLPCSFTTLPALSTGLIHLHQNIVDVQYLYGIGSAVVSFAIKWEYVL
LLFLLLADARVCACLWMMLLIAQAEAALENLVVLNSASVAGAHGILSFLVFFCAAWYIKG
RLVPGATYALYGVWPLLLLLLALPPRAYAMDREMAASCGGAVFVGLVLLTLSPYYKVFLA
RLIWWLQYFTTRAEADLHVWIPPLNARGGRDAIILLMCAVHPELIFDITKLLIAILGPLM
VLQAGITRVPYFVRAQGLIHACMLVRKVAGGHYVQMAFMKLGALTGTYIYNHLTPLRDWP
RAGLRDLAVAVEPVVFSDMETKIITWGADTAACGDIILGLPVSARRGKEILLGPADSLEG
RGLRLLAPITAYSQQTRGLLGCIITSLTGRDKNQVEGEVQVVSTATQSFLATCVNGVCWT
VYHGAGSKTLAAPKGPITQMYTNVDQDLVGWPKPPGARSLTPCTCGSSDLYLVTRHADVI
PVRRRGDSRGSLLSPRPVSYLKGSSGGPLLCPFGHAVGIFRAAVCTRGVAKAVDFVPVES
METTMRSPVFTDNSSPPAVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAA
TLGFGAYMSKAHGIDPNIRTGVRTITTGAPVTYSTYGKFLADGGCSGGAYDIIICDECHS
TDSTTILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSNTGEIPFYGKAI
PIEAIRGGRHLIFCHSKKKCDELAAKLSGLGINAVAYYRGLDVSVIPTIGDVVVVATDAL
MTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETTTVPQDAVSRSQRRGRTGRGRRGIYR
FVTPGERPSGMFDSSVLCECYDAGCAWYELTPAETSVRLRAYLNTPGLPVCQDHLEFWES
VFTGLTHIDAHFLSQTKQAGDNFPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHG
PTPLLYRLGAVQNEVTLTHPITKYIMACMSADLEVVTSTWVLVGGVLAALAAYCLTTGSV
VIVGRIILSGRPAIVPDRELLYQEFDEMEECASHLPYIEQGMQLAEQFKQKALGLLQTAT
KQAEAAAPVVESKWRALETFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTASITSP
LTTQSTLLFNILGGWVAAQLAPPSAASAFVGAGIAGAAVGSIGLGKVLVDILAGYGAGVA
GALVAFKVMSGEMPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLI
AFASRGNHVSPTHYVPESDAAARVTQILSSLTITQLLKRLHQWINEDCSTPCSGSWLRDV
WDWICTVLTDFKTWLQSKLLPQLPGVPFFSCQRGYKGVWRGDGIMQTTCPCGAQITGHVK
NGSMRIVGPKTCSNTWHGTFPINAYTTGPCTPSPAPNYSRALWRVAAEEYVEVTRVGDFH
YVTGMTTDNVKCPCQVPAPEFFSEVDGVRLHRYAPACRPLLREEVTFQVGLNQYLVGSQL
PCEPEPDVAVLTSMLTDPSHITAETAKRRLARGSPPSLASSSASQLSAPSLKATCTTHHV
SPDADLIEANLLWRQEMGGNITRVESENKVVVLDSFDPLRAEEDEREVSVPAEILRKSKK
FPAAMPIWARPDYNPPLLESWKDPDYVPPVVHGCPLPPIKAPPIPPPRRKRTVVLTESSV
SSALAELATKTFGSSESSAVDSGTATALPDQASDDGDKGSDVESYSSMPPLEGEPGDPDL
SDGSWSTVSEEASEDVVCCSMSYTWTGALITPCAAEESKLPINALSNSLLRHHNMVYATT
SRSAGLRQKKVTFDRLQVLDDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKF
GYGAKDVRNLSSKAVNHIHSVWKDLLEDTVTPIDTTIMAKNEVFCVQPEKGGRKPARLIV
FPDLGVRVCEKMALYDVVSTLPQVVMGSSYGFQYSPGQRVEFLVNTWKSKKNPMGFSYDT
RCFDSTVTENDIRVEESIYQCCDLAPEARQAIKSLTERLYIGGPLTNSKGQNCGYRRCRA
SGVLTTSCGNTLTCYLKASAACRAAKLQDCTMLVNGDDLVVICESAGTQEDAASLRVFTE
AMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWETAR
HTPVNSWLGNIIMYAPTLWARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQ
IIERLHGLSAFSLHSYSPGEINRVASCLRKLGVPPLRVWRHRARSVRARLLSQGGRAATC
GKYLFNWAVKTKLKLTPIPAASRLDLSGWFVAGYSGGDIYHSLSRARPRWFMLCLLLLSV
GVGIYLLPNR

# Drug_Target_3_Reaction:
nucleoside triphosphate + RNAn = diphosphate + RNAn+1

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
NS5B is a RNA-dependent RNA polymerase that plays an essential role in the virus replication

# Drug_Target_3_SwissProt_ID:
P26663

# Drug_Target_3_SwissProt_Name:
POLG_HCVBK

# Drug_Target_3_Synonyms:
Capsid protein C
Core protein p19
EC 2.7.7.48
EC 3.4.21.98
EC 3.4.22.-
EC 3.6.1.-
EC 3.6.1.15
Envelope glycoprotein E1
Envelope glycoprotein E2
Genome polyprotein [Contains: Core protein p21
Hepacivirin
NS1
NS3P
NS4A
NS4B
NS5A
NS5B
Non-structural protein 4A
Non-structural protein 4B
Non-structural protein 5A
Protease NS2-3
RNA-directed RNA polymerase
Serine protease/NTPase/helicase NS3
gp32
gp35
gp68
gp70
p21
p23
p27
p56
p68]
p7
p70
p8

# Drug_Target_3_Theoretical_pI:
8.14

# Drug_Target_3_Transmembrane_Regions:
169-189
359-379
726-746
758-778
783-803
814-834
882-902
929-949
1658-1678
1806-1826
1829-1849
1851-1871
1882-1902
2990-3010

#END_DRUGCARD DB04005
